Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endometrial safety and bleeding pattern study of low-dose estradiol + drospirenone versus estradiol + norethisterone acetate in postmenopausal women
2006-006199-39Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in menopause comparing Angeliq low/low with Activelle (2 arms). Primary endpoint: Endometrial hyperplasia or worse after 13 cycles. Started Apr 2007; status: completed.
02
Drugs
drospirenoneestradiol + norethindrone
03
Conditions
menopause
Beyond the preview
Go deeper on 2006-006199-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006199-39.